255 related articles for article (PubMed ID: 28417568)
1. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
[TBL] [Abstract][Full Text] [Related]
2. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
[No Abstract] [Full Text] [Related]
3. HDM2 regulation by AURKA promotes cell survival in gastric cancer.
Sehdev V; Katsha A; Arras J; Peng D; Soutto M; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Clin Cancer Res; 2014 Jan; 20(1):76-86. PubMed ID: 24240108
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
[TBL] [Abstract][Full Text] [Related]
6. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
[No Abstract] [Full Text] [Related]
8. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition.
Wang CY; Lee MH; Kao YR; Hsiao SH; Hong SY; Wu CW
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119016. PubMed ID: 33744274
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.
Katsha A; Soutto M; Sehdev V; Peng D; Washington MK; Piazuelo MB; Tantawy MN; Manning HC; Lu P; Shyr Y; Ecsedy J; Belkhiri A; El-Rifai W
Gastroenterology; 2013 Dec; 145(6):1312-22.e1-8. PubMed ID: 23993973
[TBL] [Abstract][Full Text] [Related]
13. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
[TBL] [Abstract][Full Text] [Related]
14. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
[No Abstract] [Full Text] [Related]
15. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
16. Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).
Goos JACM; Verbeek J; Geldof AA; Hiemstra AC; van de Wiel MA; Adamzek KA; Delis-Van Diemen PM; Stroud SG; Bradley DP; Meijer GA; Hoekstra OS; Fijneman RJA; Windhorst AD
Nucl Med Biol; 2016 Jan; 43(1):63-72. PubMed ID: 26432753
[TBL] [Abstract][Full Text] [Related]
17. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
18. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
19. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
20. AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.
Liu X; Li Z; Song Y; Wang R; Han L; Wang Q; Jiang K; Kang C; Zhang Q
Oncotarget; 2016 May; 7(22):33152-64. PubMed ID: 27121204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
